Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides pharmaceutical research and development services to the life sciences industry in North America, Europe, Mainland China, rest of Asia, and internationally. The company operates through five segments: Laboratory Services; Chemistry, Manufacturing and Controls (CMC) Services; Clinical Development Services; Biologics and Cell and Gene Therapy Services; and Others. It offers laboratory chemistry solutions, including medicinal, synthetic, and analytical and purification chemistry, as well as computer-aided drug design services; bioscience services comprising in vitro and in vivo drug metabolism and pharmacokinetics/absorption, distribution, metabolism, and excretion solutions; and in vitro biology and in vivo pharmacology, safety assessment, and the U.S. laboratory services. The company also provides process development and manufacturing, material science/pre-formulation, formulation development and manufacturing, and analytical development services; and radiolabelled science services and early stage clinical trial services, as well as clinical research and site management services. It also provides business development; and contract research, development, and manufacturing services for pharmaceutical products. The company was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.

Pharmaron Beijing Co., Ltd.

Pharmaron is a life science contract research organization that offers research, development, and manufacturing service capabilities throughout the drug discovery, preclinical, clinical development, and commercialization process.

	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue						3.76B -	5.13B 36.64%			11.46B -
cost of revenue						2.42B -	3.21B 32.50%			7.65B -
gross profit						1.33B -	1.92B 44.15%			3.80B -
selling and marketing expenses						72.99M -	92.64M 26.93%			252.78M -
general and administrative expenses						222.42M -	295.64M 32.92%			752.13M -
selling general and administrative expenses						295.41M -	388.28M 31.44%			1.68B -
research and development expenses						62.87M -	105.35M 67.56%			418.60M -
other expenses	6.05M -	14.60M 141.19%	24.67M 68.96%	15.55M 36.97%	20.46M 31.59%	271.96M 1,229.02%	345.31M 26.97%	591.84M 71.39%	766.00M 29.43%	-8.57M 101.12%
cost and expenses						3.05B -	4.05B 32.62%			9.77B -
operating expenses	156.87M -	224.98M 43.42%	286.00M 27.13%	388.85M 35.96%	503.53M 29.49%	630.23M 25.16%	838.94M 33.12%	1.15B 37.56%	2.02B 74.84%	2.11B 4.64%
interest expense						82.48M -	23.85M 71.08%			182.19M -
ebitda						1.02B -	1.63B 59.05%			2.70B -
operating income				262.97M -		631.49M -	1.32B 109.64%			1.69B -
depreciation and amortization	51.26M -					393.14M -	305.87M 22.20%			1.01B -
total other income expenses net						1.06M -				150.31M -
income before tax						632.55M -	1.32B 108.58%			1.84B -
income tax expense						101.88M -	172.38M 69.20%			256.11M -
net income	21.00M -	73.85M 251.73%	176.91M 139.57%	230.86M 30.49%	339.22M 46.94%	547.19M 61.31%	1.17B 114.25%	1.66B 41.68%	1.37B 17.24%	1.60B 16.48%
weighted average shs out	505.46M -	505.46M 0%	758.19M 50%	887.91M 17.11%	886.07M 0.21%	1.49B 67.73%	1.78B 19.72%	1.19B 33.26%	1.18B 0.42%	1.77B 49.90%
weighted average shs out dil	505.46M -	505.46M 0%	758.19M 50%	887.91M 17.11%	886.07M 0.21%	1.49B 67.77%	1.78B 20.05%	1.21B 32.02%	1.18B 2.39%	1.78B 49.91%
eps	0.04 -	0.38 815.66%	0.23 39.47%	0.26 13.04%	0.38 46.15%	0.37 2.63%	0.66 78.38%	1.40 112.12%	1.16 17.14%	0.90 22.41%
epsdiluted	0.04 -	0.38 815.66%	0.23 39.47%	0.26 13.04%	0.38 46.15%	0.37 2.63%	0.66 78.38%	1.37 107.58%	1.16 15.33%	0.90 22.41%

3007

COM:PHARMARON

Pharmaron

Last Close

28.38

22/11 07:04

Market Cap

31.15B

Beta: -

Volume Today

28.97M

Avg: -

Preview